Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Durvalumab for the treatment of non-small cell lung cancer.

Mezquita L, Planchard D.

Expert Rev Respir Med. 2018 Aug;12(8):627-639. doi: 10.1080/17476348.2018.1494575. Epub 2018 Jul 9.

PMID:
29958099
2.

Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.

Geraud A, Mezquita L, Bigot F, Caramella C, Planchard D, Le Pechoux C, Besse B.

J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683-X. doi: 10.1016/j.jtho.2018.05.033. [Epub ahead of print] No abstract available.

PMID:
29885478
3.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D.

Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29729495
4.

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Planchard D, Johnson BE.

Arch Pathol Lab Med. 2018 Jul;142(7):796-797. doi: 10.5858/arpa.2018-0088-ED. Epub 2018 Apr 12. No abstract available.

PMID:
29648886
5.

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Mezquita L, Planchard D.

Cancer Manag Res. 2018 Jan 18;10:123-130. doi: 10.2147/CMAR.S129963. eCollection 2018. Review.

6.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
7.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

PMID:
29327044
8.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B.

Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7.

PMID:
29191602
9.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
10.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
11.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

12.

Durvalumab in non-small-cell lung cancer patients: current developments.

Mezquita L, Planchard D.

Future Oncol. 2018 Feb;14(3):205-222. doi: 10.2217/fon-2017-0373. Epub 2017 Nov 15. Review.

PMID:
29140105
13.

AZD3759 for CNS metastases in EGFR-mutant lung cancer.

Planchard D.

Lancet Respir Med. 2017 Nov;5(11):841-842. doi: 10.1016/S2213-2600(17)30395-8. Epub 2017 Oct 19. No abstract available.

PMID:
29056569
14.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
15.

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N.

J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081.

PMID:
28967957
16.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.

PMID:
28919011
17.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.

18.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

19.

Are we reproducible in measurement of NET liver metastasis?

Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E.

Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.

PMID:
28844707
20.

Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.

Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R, Grimaldi F, Pizzolitto S, Guigay J, de Latour BR, Giuffrida D, Longchampt E, de Montpreville VT, Fadel E, Colao A, Planchard D, Papotti M, Faggiano A, Baudin E.

Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.

PMID:
28813709
21.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

PMID:
28798088
22.

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.

PMID:
28633480
23.

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Atlan P, Bayar MA, Lanoy E, Besse B, Planchard D, Ramon J, Raynard B, Antoun S.

Support Care Cancer. 2017 Nov;25(11):3365-3373. doi: 10.1007/s00520-017-3755-z. Epub 2017 Jun 8.

PMID:
28593463
24.

Targeting ALK-rearranged non-small-cell lung cancer: an update.

Sullivan I, Planchard D.

Future Oncol. 2017 Jun;13(14):1213-1217. doi: 10.2217/fon-2017-0127. Epub 2017 Jun 7. No abstract available.

PMID:
28589737
25.

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.

Planchard D, Remon J, Nowak F, Soria JC.

Am Soc Clin Oncol Educ Book. 2017;37:12-17. doi: 10.14694/EDBK_100007. No abstract available.

26.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.

27.

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.

Boros A, Lacroix L, Lacas B, Adam J, Pignon JP, Caramella C, Planchard D, de Montpreville V, Deutsch E, Levy A, Besse B, Le Pechoux C.

Oncotarget. 2017 Apr 11;8(15):25189-25199. doi: 10.18632/oncotarget.15966.

28.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.

PMID:
28242503
29.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA.

J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.

PMID:
28221867
30.

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.

Sullivan I, Planchard D.

Front Med (Lausanne). 2017 Jan 18;3:76. doi: 10.3389/fmed.2016.00076. eCollection 2016. Review.

31.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.

PMID:
28104619
33.

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O.

Invest New Drugs. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12.

PMID:
27838867
34.

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM.

Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11.

35.

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

Facchinetti F, Caramella C, Auger N, Planchard D, Adam J, Lacroix L, Remon J, Massard C, Soria JC, Friboulet L, Besse B.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000520.

PMID:
27197808
37.

Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.

Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B.

Lung Cancer. 2016 Sep;99:111-6. doi: 10.1016/j.lungcan.2016.06.020. Epub 2016 Jul 1.

PMID:
27565923
38.

Reply to N. Singh et al.

Planchard D.

J Clin Oncol. 2016 Nov 20;34(33):4055-4056. doi: 10.1200/JCO.2016.68.9349. Epub 2016 Oct 31. No abstract available.

PMID:
27551135
39.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. Epub 2016 Jul 11.

40.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

41.

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC.

Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17.

42.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.

Oncoimmunology. 2015 Aug 12;5(4):e1071008. eCollection 2016 Apr.

43.

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

Walter T, Planchard D, Bouledrak K, Scoazec JY, Souquet PJ, Dussol AS, Guigay J, Hervieu V, Berdelou A, Ducreux M, Arpin D, Lombard-Bohas C, Baudin E.

Lung Cancer. 2016 Jun;96:68-73. doi: 10.1016/j.lungcan.2016.03.018. Epub 2016 Mar 31.

PMID:
27133753
44.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE.

Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.

45.

Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo.

Schuler M, Yang JC, Planchard D.

Ann Oncol. 2016 Jun;27(6):1172-3. doi: 10.1093/annonc/mdw144. Epub 2016 Mar 30. No abstract available.

PMID:
27029703
46.

Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

Planchard D.

J Clin Oncol. 2016 Apr 20;34(12):1292-4. doi: 10.1200/JCO.2015.66.3344. Epub 2016 Mar 14. No abstract available.

PMID:
26976417
47.

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA.

Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76. doi: 10.1007/s00280-016-2992-z. Epub 2016 Feb 22.

PMID:
26902828
48.

Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.

Sullivan I, Planchard D.

Future Oncol. 2016 Apr;12(7):945-61. doi: 10.2217/fon.16.15. Epub 2016 Feb 19. Review.

PMID:
26892300
49.

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F.

J Crohns Colitis. 2016 Apr;10(4):395-401. doi: 10.1093/ecco-jcc/jjv227. Epub 2016 Jan 18.

50.

[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].

Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S.

Ann Pathol. 2016 Jan;36(1):94-102. doi: 10.1016/j.annpat.2015.11.004. Epub 2016 Jan 14. French.

PMID:
26778219

Supplemental Content

Loading ...
Support Center